Management of Castration-Resistant Prostate Cancer: A Global Approach

Abstract

Treatment options for castration-resistant prostate cancer (CRPC) have evolved since the start of the 2000s, with most of the new effective therapies appearing since 2010. In 2004, docetaxel was the first chemotherapeutic agent to improve survival in CRPC, but little else was available once patients recurred. Since 2010, four new options have been shown to improve survival in patients with refractory or recurring disease after docetaxel. In the management of bone metastases, two bone-targeted therapies have been shown to reduce the risk of bone complications, and they are part of the overall management strategy in CRPC patients. Therapeutic options before chemotherapy have shown promising results and may soon become available in Canada. The present article reviews the treatment options that have shown to be effective in CRPC and also some of the ongoing work in the field.

Management of Patients with Castration-resistant Metastatic Prostate Cancer

“…Najnovšie aj monoklonálna protilátka denosumab (inhibítor aktivity osteoklastov, inhibítor RANKreceptoru aktivovaného nukleárneho faktoru κ) v dávke 120 mg subkutánne každé štyri týždne má signifi kantný účinok pri prevencii SRE (zníženie ich výskytu, zníženie počtu patologických fraktúr, predĺženie doby do vzniku prvej SRE a tiež pri zmiernení bolestí [38,39].…”